-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 11, the official website of NMPA showed that CSPC's mitoxantrone hydrochloride liposome injection and lenvatinib mesylate capsules were approved for marketing
Lenvatinib mesylate capsules is a multi-target receptor tyrosine kinase inhibitor developed by Eisai and Merck.
The market size of lenvatinib mesylate capsules continued to rise after the launch
Sales of Eisai Lenvatinib in China (unit: RMB million)
Source: Sales Database of Multinational Listed Companies on Minet.
With the approval of this product from CSPC, 8 local companies have been approved for production of lenvatinib mesylate capsules in the domestic market
It is worth noting that there are currently 8 companies that have passed the evaluation of lenvatinib mesylate capsules, forming an 8+1 competition pattern, and they are likely to be included in the upcoming seventh batch of centralized procurement
Note: The original text has been deleted
Data source: Minet database, NMPA